All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2026-09-01.
From the record
Crinetics Pharmaceuticals, Inc.'s filings since 2017 show 2 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, the latest 2026-09-01); an auditor change (8-K item 4.01, the latest 2026-03-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+33.1% a year over 10 filed years; profitable in 0 of 10.
From the record
Crinetics Pharmaceuticals, Inc.'s 10 filed years say what it did: revenue went from $589 thousand in fiscal 2016 to $8 million in fiscal 2025, up 33.1% a year; it rose in 3 of 7 years; the deepest fall was 100% from fiscal 2018 to fiscal 2021; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Crinetics Pharmaceuticals, Inc.'s shareholder treatment is put at 4.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 48% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -47%: lost 47¢ per shareholder dollar. Leverage 12%: owes 12¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Crinetics Pharmaceuticals, Inc. lost about 47 cents for every dollar of shareholders' money, and gross profitability: its products earned about 1 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 12 cents per dollar of assets, and net share issuance: its share count grew 16.4% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 26% of 315 in its family; net margin -6046.2%.
From the record
Crinetics Pharmaceuticals, Inc.'s standing among 315 graded names in its industry family: revenue of $8 million in fiscal 2025 ranks in the bottom 39% by size; a net margin of -6046.2% ranks in the bottom 13% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 43% of 315 in its family for leadership; chief executive since 2018.
From the record
Crinetics Pharmaceuticals, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Struthers, Richard Scott (President & CEO, as filed), filing under that title since 2018-07-17, 8.3 years (top 22% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.1 years (bottom 36%); 12 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 14%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 50% of 273 in its family for room to expand.
From the record
Crinetics Pharmaceuticals, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $102 million against no long-term debt tagged leaves 9.1% of its assets as net cash, bottom 24% of its family; cash from operations less capital spending is -4985.5% of revenue (bottom 12%); a gross margin of 86% (top 26%); research spending of 4314.7% of revenue (top 11%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 11% of 306 in its family for growth drivers.
From the record
Crinetics Pharmaceuticals, Inc.'s growth drivers, from the filed years to fiscal 2025: the newest year grew 641.7% (top 5%); research spending grew 36.6% a year (top 12%); capital spending grew 51.5% a year (top 14%) (its annual reports). Crinetics Pharmaceuticals, Inc. reported 2 product lines in fiscal 2025: Product at $5 million (70%), License and Service at $2 million (30%); 1 of 1 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 46% of 233 in its family for expectations against reality.
From the record
Crinetics Pharmaceuticals, Inc.'s newest year against its own record: net income of $465 million against a prior three-year average of $226 million (bottom 14%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 6%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made